Dog Vaccine Market Size & Share 2026-2035

Dog Vaccine Market Size

The global dog vaccine market was valued at USD 2.5 billion in 2025. The market size is projected to increase from USD 2.8 billion in 2026 to USD 5.2 billion by 2035, with a CAGR of 7.3% over the analysis period, according to the latest report published by Global Market Insights, Inc.

The expansion of the market is driven by increasing awareness of pet health, coupled with the rising incidence of canine diseases such as rabies, parvovirus, and distemper, which underscore the need for vaccinations. Additionally, rising pet ownership and growing emphasis on preventive healthcare for dogs are expected to propel the vaccine market significantly.

According to the American Pet Products Association (2023-2024), 66% of U.S. households, representing approximately 86.9 million homes, own a pet; among these, dogs are the most popular, with approximately 65.1 million households owning a dog. The report also states that millennials constitute the largest share of current pet owners (33%), followed by Gen X (25%) and baby boomers (24%). Similarly, an article published by Women's Health (Hearst UK) in May 2023 highlighted a survey revealing that 63% of millennials are investing more in their dogs than themselves. This indicates strong potential for industry growth in the coming years.

Between 2022 and 2024, the dog vaccines market experienced steady growth, driven by rising dog ownership and increased consumer spending on pets. According to the American Pet Products Association (APPA), total U.S. pet industry expenditures increased from USD 136.8 billion in 2022 to USD 147 billion in 2023 and further to about USD 152 billion in 2024, reflecting the increasing willingness of pet owners to spend on pet healthcare, nutrition, and wellness products.

Additionally, dog ownership continues to expand, with the American Veterinary Medical Association reporting that 45.5% of U.S. households owned at least one dog in 2024, indicating the widespread adoption of dogs as companion animals and reinforcing their dominant position among pets. Consequently, the rise in both dog ownership and expenditure between 2022 and 2024 has significantly supported the expansion of the companion animal healthcare and pet care markets.

A dog vaccine is a biological preparation that helps protect dogs from various diseases by stimulating their immune system to recognize and fight against specific pathogens.  Vaccines contain antigens that mimic disease-causing agents, triggering an immune response without causing illness. This prepares the dog's immune system to recognize and respond to future infections, reducing the risk of serious illness or death. Key players in the market include Zoetis, Merck & Co., Inc., Boehringer Ingelheim, Elanco Animal Health, and Virbac, which offer a wide range of canine vaccines and preventive healthcare solutions globally.

Dog Vaccine Market Trends

• Government initiatives for animal healthcare, such as subsidized vaccination programs and public awareness campaigns to address the infection burden, propel the need for animal vaccines. These initiatives encourage higher vaccination rates and foster a healthier pet population.
• For instance, the National Rabies Control Programme (NRCP) launched by the Government of India in 2021 focuses on mass dog vaccination and public awareness to eliminate rabies by 2030. The program promotes large-scale anti-rabies vaccination campaigns for dogs through collaboration with veterinary departments and animal welfare organizations. Such initiatives help increase vaccination coverage among dogs, reduce the transmission of zoonotic diseases, and encourage wider adoption of canine vaccines, thereby supporting the growth of the dog vaccine market.
• Innovation in vaccine technology is another significant trend that is positively influencing the growth of the market. There is an increase in the development of recombinant vaccines, DNA vaccines, and combination vaccines that offer immunity against various diseases in a single dose. Such advanced vaccines offer better efficacy and convenience while reducing the number of injections needed. Continuous investment in veterinary biologics research is enabling companies to introduce more effective and long-lasting immunization solutions, thus driving the market growth.
• Lastly, the growing adoption of pet insurance is emerging as an important trend supporting the dog vaccines market. According to the North American Pet Health Insurance Association, the number of insured pets in the U.S. increased to approximately 6.25 million in 2023, representing a 17% increase compared to 2022.
• Dogs account for the majority of insured pets, reflecting their high healthcare expenditure and frequent veterinary visits. As more pet owners opt for insurance coverage to manage veterinary costs, routine preventive care such as vaccinations, wellness checkups, and parasite control is becoming more accessible, thereby contributing to higher vaccination rates and supporting the growth of the market.

Dog Vaccines Market Analysis

Based on the vaccine type, the dog vaccine market is categorized into live attenuated, inactivated, recombinant, and other vaccine types. The live attenuated segment is set to lead the market, accounting for the largest revenue of USD 1.1 billion in 2025 and expected to maintain its dominance throughout the forecast period with a significant growth rate.

• Live attenuated vaccines use weakened forms of the pathogen, stimulating a robust immune response without causing the disease. This results in effective and durable protection against various canine diseases, thereby proving to be the preferred choice.
• Also, these vaccines often require fewer doses, making them more convenient for pet owners and veterinarians.
• Their ability to induce both cellular and humoral immunity further enhances their effectiveness.
• As a result, they are widely preferred and trusted in the veterinary community, contributing to their dominance in the dog vaccine market.
• The recombinant vaccine segment, on the other hand, is expected to grow at a CAGR of 7.6% over the analysis period. Factors such as advancements in veterinary biotechnology, improved safety profiles compared to traditional live vaccines, and the ability of recombinant vaccines to provide targeted immune responses are driving segment growth.

Based on the disease type, the dog vaccine market is classified into canine distemper, canine infectious respiratory disease complex (CIRDC), canine parvovirus, canine leptospirosis, canine lyme disease, infectious canine hepatitis, canine rabies, and other disease types. The canine parvovirus segment holds the largest market share in 2025 and is expected to grow at a CAGR of 7.4% over the analysis period.

• Canine parvovirus dominance can be attributed to its high contagiousness and severe impact on canine health. Canine parvovirus is estimated to affect over 330,000 puppies annually, with as many as 91% facing mortality if untreated. This virus, particularly dangerous for puppies, leads to severe gastrointestinal disorders and dehydration. Therefore, the high mortality rate and rapid spread of parvovirus create a significant demand for effective vaccination.
• Moreover, the introduction of new vaccines along with awareness of parvovirus among owners will spur the segment growth.
• For instance, Elanco Animal Health Incorporated launched a comprehensive educational campaign, designated as the inaugural National Parvo Awareness Day, to raise awareness about the severe and frequently fatal puppy disease. As a component of this campaign, Elanco introduces "Parvo is Poop," an engaging initiative that elucidates the virus's transmission, symptoms, and innovative treatment for canine parvovirus (parvo). This initiative aims to spread awareness to address the challenges posed by parvovirus and enhance the dog's health globally.

Based on the route of administration, the dog vaccine market is segmented into intranasal, injectable, and oral. The injectable segment dominated the market in 2025 with a market share of 75%.

• The injectable segment accounts for the largest share of the market, primarily due to its proven effectiveness, precise dosage delivery, and ability to generate strong and consistent immune responses.
• Injectable vaccines are widely used in veterinary practice as they allow controlled administration by professionals. Their reliability and established clinical use make them the preferred vaccination method in routine immunization programs.
• Further innovations in injectable vaccines are aiding adoption rates. For example, in March 2021, Merck & Co., Inc. introduced Nobivac Respira, a single-dose injectable vaccine that protects against Bordetella bronchiseptica. Such product innovations, along with strong veterinary preference in injectable formulations, continue to reinforce the segment’s dominant position and support the growth of the market.

Based on the end use, the dog vaccines market is segmented into veterinary hospitals, veterinary clinics, and research institutes. The veterinary hospitals segment is projected to reach USD 2.4 billion by the end of 2035.

• Veterinary hospitals offer comprehensive medical services, including vaccinations, making them a preferred choice for pet owners seeking preventive care for their dogs.
• Also, these facilities have well-trained staff, advanced equipment, and established trust with pet owners, leading to higher vaccination rates.
• Moreover, veterinary hospitals often provide tailored vaccination schedules and recommendations based on individual pet needs, further solidifying their dominance in the market for dog vaccines.

North America Dog Vaccine Market

North America dominated the global dog vaccines industry with a market share of 45.7% in 2025.

• North America holds the largest share of the market, driven by high pet ownership, advanced veterinary healthcare infrastructure, and strong awareness of preventive animal healthcare.
• The region has a large dog population and high spending on pet healthcare services, which supports the adoption of routine vaccination.
• Additionally, strict vaccination guidelines and widespread veterinary services across the region encourage regular immunization of dogs against diseases such as rabies, distemper, and parvovirus.
• The presence of leading animal health companies such as Zoetis and Merck & Co., Inc. further strengthens North America’s dominant position in the market.

The U.S. dominated the North American dog vaccines market, accounting for USD 0.8 billion and USD 0.9 billion in 2022 and 2023, respectively. The market size reached USD 1.1 billion in 2025, growing from USD 1 billion in 2024.

• The U.S. boasts a large population of pet dogs with millions of households owning at least one canine companion. For instance, an article published by My Golden Retriever Puppies in August 2023, reported that dogs and cats are globally cherished and widely favored as pets, with the U.S. alone hosting an estimated 89.7 million pet dogs. This high pet ownership rate creates a substantial market for dog vaccines.

• Also, the U.S. has a well-developed veterinary healthcare infrastructure, including veterinary clinics, hospitals, and research institutions, facilitating widespread access to vaccination services.
• Further, the presence of leading companies and innovative research in the U.S. also contributes to its dominance, with the country often being at the forefront of advancements in companion drug and vaccine development. Such factors are expected to spur the country-level market growth.

Europe Dog Vaccine Market

Europe holds a significant share of the dog vaccines industry, supported by high pet ownership rates, strong regulatory frameworks for animal health, and well-established veterinary healthcare systems.

• Several European countries have implemented strict vaccination guidelines to control infectious and zoonotic diseases in companion animals.
• According to the FEDIAF, over 90 million households in Europe owned at least one pet in 2023, including around 106 million dogs, highlighting the large companion animal population in the region.
• This substantial dog population increases the demand for routine vaccination and preventive veterinary care.
• In addition, the presence of leading animal health companies such as Virbac and Boehringer Ingelheim further supports the growth of the market across Europe.

Germany exhibited a high growth potential in the European dog vaccines market.

• Germany plays a significant role in the European dog vaccines industry due to its extensive scientific research, innovation, and development in animal health. Germany's strong research infrastructure and regulatory environment support the development of new vaccines and ensure their safety and efficacy.
• Further, the country's high pet ownership rate, particularly for dogs, drives demand for dog vaccines.

Asia Pacific Dog Vaccine Market

The Asia Pacific dog vaccines industry is poised for rapid growth with a CAGR of 8% during the forecast period.

• The Asia Pacific region offers substantial growth potential in the dog vaccine industry, driven by increasing urbanization, higher disposable incomes, and changing lifestyles. As more households welcome dogs into their families, the demand for pet healthcare, including vaccinations, has surged.
• Also, government initiatives promoting responsible pet ownership and public health awareness campaigns also play a key role in driving vaccine uptake. For instance, in 2022, the Brihanmumbai Municipal Corporation (BMC) partnered with Mission Rabies to pursue a rabies-free status for Mumbai, India. A pilot program in September and October inoculated over 14,000 dogs, while a 2024 drive aligns with a national initiative to eliminate rabies in India by 2030, intending to vaccinate thousands more. This collaborative effort, aimed at accelerating vaccination programs, is expected to supplement the market expansion.

China is expected to witness significant growth in the Asia Pacific dog vaccine market.

• Rapid urbanization, changing lifestyles, and the growing trend of pet humanization have led to a surge in dog adoption across major Chinese cities.
• According to the China Pet Industry Association, the number of pet dogs in urban China exceeded 51 million in 2023, reflecting the expanding companion animal population in the country. This growing dog population, combined with increasing awareness of preventive veterinary care and vaccination against diseases such as rabies and distemper, is expected to boost demand for canine vaccines.
• In addition, the expansion of veterinary clinics is further supporting the growth of the market in China.

Latin America Dog Vaccine Market

Brazil is witnessing rapid growth in the Latin America dog vaccines industry.

• Brazil represents a key market for dog vaccines in Latin America due to its large companion animal population and increasing focus on animal disease prevention.
• According to the Instituto Pet Brasil, Brazil had over 60 million dogs in 2023, making it one of the largest dog populations globally.
• The rising adoption of pets, along with growing awareness of preventive veterinary care and nationwide rabies vaccination campaigns, is driving demand for canine vaccines.

Middle East & Africa Dog Vaccine Market

South Africa dog vaccine industry is anticipated to witness substantial growth over the forecast period.

• South Africa is emerging as an important market for dog vaccines in the Middle East & Africa region, supported by a significant dog population and ongoing efforts to control zoonotic diseases such as rabies.
• According to the World Organization for Animal Health, rabies remains endemic in several African countries, leading to increased emphasis on dog vaccination programs as a key prevention strategy.
• Government-led and non-profit mass dog vaccination campaigns are actively conducted to reduce rabies transmission. These initiatives, along with increasing awareness of pet healthcare and improved access to veterinary services, are expected to drive the demand for canine vaccines in South Africa.

Dog Vaccine Market Share

The dog vaccines industry is characterized by the presence of several global animal health companies focusing on vaccine innovation and expanding their companion animal product portfolios. Key players such as Zoetis, Merck & Co., Inc., Boehringer Ingelheim, Elanco Animal Health, and Virbac collectively account for ~67% of the global market. These players maintain a strong market position through extensive vaccine portfolios, global distribution networks, and continuous investments in veterinary biologics research.

In addition, emerging players are increasingly gaining attention in the dog vaccines market by focusing on innovative vaccine technologies and niche animal health solutions. Further, smaller biotechnology firms and regional manufacturers are expanding their presence through strategic partnerships, contract manufacturing, and targeted vaccine development for companion animals. These emerging companies are contributing to innovation and competition in the animal health sector by developing next-generation biologics and expanding access to veterinary vaccines in underserved markets.

Dog Vaccine Market Companies

Some of the prominent players operating in the dog vaccines industry include:

• Bioveta
• Boehringer Ingelheim International
• Brilliant Bio Pharma
• Biogénesis Bagó
• Ceva Santé Animale
• Elanco Animal Health Incorporated
• HIPRA
• Indian Immunologicals Limited
• Merck & Co., Inc.
• NEOTECH
• Tecnovax
• Virbac
• Zendal Group
• Zoetis

• Zoetis

Zoetis is a leading player in the global dog vaccines market with a strong portfolio of companion animal vaccines. The company offers the Vanguard range of canine vaccines that protect against diseases such as canine distemper, adenovirus, parvovirus, leptospirosis, and canine influenza, strengthening its presence in preventive veterinary healthcare.

• Boehringer Ingelheim

Boehringer Ingelheim also holds a significant position in the dog vaccines industry through its Eurican and IMRAB vaccine portfolios. These vaccines provide protection against multiple canine diseases including distemper, parvovirus, adenovirus, leptospirosis, and rabies, supporting the company’s strong global presence in veterinary biologics.

Dog Vaccine Industry News:

• In March 2024, Zendal Group launched a recombinant DNA-based vaccine developed in collaboration with the Spanish National Research Council to combat canine leishmaniasis. The vaccine, known as Neoleish, targets the Leishmania parasite, which can cause severe health complications in dogs, including skin ulcers and inflammation of the liver and spleen. Studies indicate that the vaccine can reduce the presence of the parasite in infected dogs by more than 90%, helping control a disease that is also considered a zoonotic threat to humans.
• In June 2024, Merck & Co., Inc. expanded its companion animal vaccine portfolio in Canada with the launch of the NOBIVAC NXT Rabies product line. The portfolio includes NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies, developed using advanced RNA particle technology to provide effective rabies protection while maintaining strong safety and immune responses. This launch highlights the company’s continued focus on innovation and strengthening rabies prevention programs in companion animals.
• In March 2024, Merck Animal Health, collaborating with Mission Rabies, is committed to aiding the ambitious global objective of the United Against Rabies Forum, aiming for zero human deaths from dog-mediated rabies by 2030. Their contribution includes donations of NOBIVAC rabies vaccines, extending over the next five years. These donations will fulfill the annual rabies vaccine needs of the non-profit organization. This partnership underscores the dedication of both entities to combatting rabies and saving lives globally.
• In March 2024, Petia Vet Health, a subsidiary of the Zendal group, launched the Neoleish vaccine, the first vaccine for animal mammals based on recombinant DNA, to address canine leishmaniasis. Dedicated to pet health, Petia Vet Health will oversee the vaccine's marketing in Spain. This innovative vaccine launched marked a significant advancement in combating canine leishmaniasis and explored an opportunity in the animal healthcare sector.
• In November 2021, Ceva Santé Animale expanded its vaccine production capacity in Europe by investing in a new cryogenic storage facility in Monor, Hungary. The facility was designed to strengthen the company’s vaccine manufacturing and storage capabilities, enabling efficient large-scale production and distribution of veterinary vaccines.

The dog vaccines market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Vaccine Type

• Live attenuated
• Inactivated
• Recombinant
• Other vaccine types

Market, By Disease Type

• Canine distemper
• Canine infectious respiratory disease complex (CIRDC)
• Canine parvovirus
• Canine leptospirosis
• Canine lyme disease
• Infectious canine hepatitis
• Canine rabies
• Other disease types

Market, By Route of Administration

• Intranasal
• Injectable
• Oral

Market, By End Use

• Veterinary hospitals
• Veterinary clinics
• Research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE